Last reviewed · How we verify
CTP0301-A
CTP0301-A is a small molecule that targets the SGLT2 receptor.
CTP0301-A is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | CTP0301-A |
|---|---|
| Also known as | PEG 3350 |
| Sponsor | Taejoon Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
CTP0301-A works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in patients with type 2 diabetes. By reducing glucose reabsorption, CTP0301-A also has a diuretic effect, which can help to reduce blood pressure.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CTP0301-A CI brief — competitive landscape report
- CTP0301-A updates RSS · CI watch RSS
- Taejoon Pharmaceutical Co., Ltd. portfolio CI